Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

8.910 -0.090 (-1.00%)
Streaming Delayed Price Updated: 9:58 AM EST, Jan 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Organon & Co. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape
As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026
As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
A Look at Organon's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
Nasdaq, S&P 500 Futures Rise As Trump Diffuses Tariff Risk: Why INTC, MSFT, NFLX, RKLB, OGN Are On Traders' Radar Today ↗
Retail sentiment on Stocktwits for SPY and QQQ remains ‘bearish,’ signaling caution. 
Via Stocktwits
Topics ETFs Earnings Economy
News headline image
Why Are Organon (OGN) Shares Soaring Today
Shares of pharmaceutical company Organon (NYSE:OGN) jumped 8.9% in the afternoon session after reports surfaced that Sun Pharmaceutical Industries submitted a non-binding proposal to acquire the... 
Via StockStory
Topics Artificial Intelligence Initial Public Offering Supply Chain
News headline image
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
From Organon & Co.
Via Business Wire
News headline image
3 Small-Cap Stocks We Approach with Caution
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
News headline image
3 Healthcare Stocks with Questionable Fundamentals
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have... 
Via StockStory
Topics Stocks
News headline image
Why Organon (OGN) Shares Are Trading Lower Today
Shares of pharmaceutical company Organon (NYSE:OGN) fell 4.7% in the afternoon session after Barclays initiated coverage on the company with an 'Underweight' rating and a price target of $7.50. The new... 
Via StockStory
Topics Initial Public Offering
News headline image
3 Stocks Under $10 We Steer Clear Of
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be... 
Via StockStory
News headline image
3 Value Stocks with Questionable Fundamentals
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
News headline image
3 Cash-Producing Stocks We Find Risky
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
Organon (OGN): Buy, Sell, or Hold Post Q3 Earnings?
Over the past six months, Organon’s stock price fell to $7.77. Shareholders have lost 16.1% of their capital, which is disappointing considering the S&P 500 has climbed by 14.7%. This may have... 
Via StockStory
Topics Stocks
News headline image
Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
From Organon & Co.
Via Business Wire
News headline image
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
From Organon & Co.
Via Business Wire
News headline image
The 5 Most Interesting Analyst Questions From Organon’s Q3 Earnings Call
Organon's third quarter was marked by better-than-expected top-line and bottom-line results, which were well received by the market. Management attributed the quarter’s outperformance to strong... 
Via StockStory
Topics Earnings
News headline image
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Organon (OGN) Stock Trades Down, Here Is Why
Shares of pharmaceutical company Organon (NYSE:OGN) fell 2.9% in the afternoon session after the company lowered its full-year sales guidance and analysts subsequently cut their price targets on the... 
Via StockStory
Topics Artificial Intelligence Initial Public Offering Supply Chain
News headline image
Organon Analysts Cut Their Forecasts Following Q3 Results ↗
 
Via Benzinga
News headline image
OGN Q3 2025 Deep Dive: Leadership Changes, Portfolio Shifts, and Guidance Recalibration
Pharmaceutical company Organon (NYSE:OGN) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 1.3% year on year to $1.60 billion. On the other hand, the company’s... 
Via StockStory
News headline image
Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday? ↗
Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk assets amid encouraging signs from Washington that the record-long government... 
Via Benzinga
News headline image
Organon Cuts 2025 Sales Outlook Despite Earnings Beat ↗
Organon posts Q3 EPS of $1.01, topping estimates, trims 2025 sales outlook, and highlights positive Vtama data in children with atopic dermatitis. 
Via Benzinga
News headline image
Organon (NYSE:OGN) Posts Better-Than-Expected Sales In Q3
Pharmaceutical company Organon (NYSE:OGN) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 1.3% year on year to $1.60 billion. On the other hand, the company’s... 
Via StockStory
News headline image
Organon Reports Results for the Third Quarter Ended September 30, 2025
From Organon & Co.
Via Business Wire
News headline image
Organon (OGN) Reports Earnings Tomorrow: What To Expect
Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Monday before market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities
From Organon & Co.
Via Business Wire
News headline image
Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie
From Organon & Co.
Via Business Wire
News headline image
Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025
From Organon & Co.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.